Bolt Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
28/03/2025 12:00
Bolt Biotherapeutics Inc BOLT.OQ reported a quarterly adjusted loss of 38 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -47 cents. The mean expectation of four analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -41 cents to -34 cents per share. Reported revenue was zero; analysts expected $790.00 thousand. Bolt Biotherapeutics Inc's reported EPS for the quarter was a loss of 42 cents. The company reported a quarterly loss of $15.94 million. Bolt Biotherapeutics Inc shares had fallen by 17.9% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold" Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $1.13 This summary was machine generated from LSEG data March 28 at 12:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.38 | -0.38 | Met |
| Sep. 30 2024 | -0.35 | -0.40 | Missed |
| Jun. 30 2024 | -0.48 | -0.46 | Beat |
| Mar. 31 2024 | -0.51 | -0.28 | Beat |